The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03618095




Registration number
NCT03618095
Ethics application status
Date submitted
1/08/2018
Date registered
7/08/2018
Date last updated
15/08/2019

Titles & IDs
Public title
REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects
Scientific title
REPRISE IV: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of LOTUS Edge Valve System in IntermediatE Surgical Risk Subjects
Secondary ID [1] 0 0
S2354
Universal Trial Number (UTN)
Trial acronym
REPRISE IV
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Aortic Valve Stenosis 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - LOTUS Edge Valve System

Experimental: Main Cohort - Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System

Experimental: Roll-In Cohort - Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System

Experimental: Bicuspid Cohort - Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System


Treatment: Devices: LOTUS Edge Valve System
TAVR with the LOTUS Edge Valve System

Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Composite of all-cause mortality and all stroke. - Critical safety events that are observed in the elderly population undergoing TAVR; assessments recommended by VARC
Timepoint [1] 0 0
1 year post index procedure and device implantation

Eligibility
Key inclusion criteria
- Subject has documented severe aortic stenosis defined as initial AVA =1.0 cm2 (or AVA
index =0.6 cm2/m2) AND a mean pressure gradient =40 mm Hg OR maximal aortic valve
velocity =4.0 m/s OR Doppler velocity index =0.25 as measured by echocardiography
and/or invasive hemodynamics. Note: In cases of low flow, low gradient aortic stenosis
with left ventricular dysfunction (ejection fraction <50%), dobutamine can be used to
assess the grade of aortic stenosis (maximum dobutamine dose of 20 mcg/kg/min
recommended)c; the subject may be enrolled if echocardiographic criteria are met with
this augmentation. (IC1)

- A subject in the Bicuspid Aortic Valve Nested Registry cohort must have a documented
Sievers Type 0 or Sievers Type 1 bicuspid aortic valve based on CT assessment and
confirmed by the CT core lab with hemodynamic parameters that meet the criteria in
IC1.

- Subject has a documented aortic annulus size of =20 mm and =27 mm based on the
center's assessment of pre-procedure diagnostic imaging (and confirmed by the Case
Review Committee [CRC]).

- Subject has symptomatic aortic valve stenosis per IC1 definition above with NYHA
Functional Class = II.

- Heart team (which must include an experienced cardiac interventionalist and an
experienced cardiac surgeon) agrees that the subject is at intermediate risk of
operative mortality (=3% and <8% at 30 days based on the Society of Thoracic Surgeons
[STS] risk score and other clinical comorbidities unmeasured by the risk calculator)
and TAVR is appropriate. Note: Risk of operative mortality must be assessed via an
in-person evaluation by a center cardiac surgeon and must be confirmed by the CRC
(which must include an experienced cardiac surgeon).

- Heart team agrees that the subject is likely to benefit from valve replacement. IC7.
Subject (or legal representative) has been informed of the study requirements and the
treatment procedures, and provides written informed consent.

- Subject, family member, and/or legal representative agree(s) and subject is capable of
returning to the study hospital for all required scheduled follow-up visits.

- Subject is expected to be able to take the protocol-required adjunctive pharmacologic
therapy.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Subject has a unicuspid or bicuspid aortic valve (not applicable to subjects in the
Bicuspid Nested Registry cohort).

- Subjects in the Bicuspid Nested Registry cohort will have a documented Sievers Type 0
or Sievers Type 1 bicuspid aortic valve based on CT assessment and confirmed by the CT
core lab. Subjects are not eligible for inclusion in the Bicuspid Nested Registry
cohort if the maximum diameter of the ascending aorta is >45 mm or if the subject has
another indication for aortic root replacement. Subjects with a Sievers Type 2
bicuspid valve are not eligible for enrollment in any study cohort.

- Subject has had an acute myocardial infarction within 30 days prior to the index
procedure (defined as Q-wave MI or non-Q-wave MI with total CK elevation = twice
normal in the presence of CK-MB elevation and/or troponin elevation).

- Subject has had a cerebrovascular accident or transient ischemic attack clinically
confirmed by a neurologist or neuroimaging within the past 6 months prior to study
enrollment.

- Subject is on renal replacement therapy or has GFR <20 (based on hospital preferred
method). See AEC1 below if subject is in the CT Imaging Substudy.

- Subject has a pre-existing prosthetic aortic or mitral valve.

- Subject has severe (4+) aortic, tricuspid, or mitral regurgitation.

- Subject has moderate to severe mitral stenosis (mitral valve area =1.5 cm2 and
diastolic pressure half-time =150 ms, Stage C or Dc).

- Subject has a need for emergency surgery for any reason.

- Subject has a history of endocarditis within 6 months of index procedure or evidence
of an active systemic infection or sepsis.

- Subject has echocardiographic evidence of new intra-cardiac vegetation or
intraventricular or paravalvular thrombus requiring intervention.

- Subject has platelet count <50,000 cells/mm3 or >700,000 cells/mm3, or white blood
cell count <1,000 cells/mm3.

- Subject will refuse transfusions or has had a gastrointestinal bleed requiring
hospitalization or transfusion within the past 3 months, or has other clinically
significant bleeding diathesis or coagulopathy that would preclude treatment with
required antiplatelet regimen.

- Subject has known hypersensitivity to contrast agents that cannot be adequately
pre-medicated, or has known hypersensitivity to aspirin, all P2Y12 inhibitors,
heparin, nickel, tantalum, titanium, or polyurethanes.

- Subject has a life expectancy of less than 24 months due to non-cardiac, comorbid
conditions based on the assessment of the investigator at the time of enrollment.

- Subject has hypertrophic cardiomyopathy.

- Subject has any therapeutic invasive cardiac or vascular procedure within 30 days
prior to the index procedure (except for balloon aortic valvuloplasty or pacemaker or
implantable cardioverter defibrillator implantation, which are allowed).

- Subject has multivessel coronary artery disease with a Syntax score >22, and/or an
unprotected left main coronary artery.

- Subject has severe left ventricular dysfunction with ejection fraction <20%.

- Subject is in cardiogenic shock or has hemodynamic instability requiring inotropic
support or mechanical support devices.

- Subject has arterial access that is not acceptable for the study device delivery
system as defined in the device Instructions For Use.

- Subject has severe vascular disease that would preclude safe access (e.g., aneurysm
with thrombus that cannot be crossed safely; marked tortuosity; significant narrowing
of the abdominal aorta; severe unfolding of the thoracic aorta; or thick, protruding,
ulcerated atheroma in the aortic arch).

- Subject has current problems with substance abuse (e.g., alcohol, etc.) that may
interfere with the subject's participation in this study.

- Subject is participating in another investigational drug or device study that has not
reached its primary endpoint.

- Subject has untreated conduction system disorder (e.g., Type II second degree
atrioventricular block) that in the opinion of the treating physician is clinically
significant and requires a pacemaker implantation. Enrollment is permissible after
permanent pacemaker implantation.

- Subject has severe incapacitating dementia.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Monash Cardiovascular Research Centre - Clayton
Recruitment postcode(s) [1] 0 0
3168 - Clayton
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Montana
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
Tennessee
Country [19] 0 0
United States of America
State/province [19] 0 0
Texas
Country [20] 0 0
United States of America
State/province [20] 0 0
Washington
Country [21] 0 0
United States of America
State/province [21] 0 0
Wisconsin

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Boston Scientific Corporation
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
REPRISE IV: REpositionable Percutaneous Replacement of Stenotic Aortic Valve through
Implantation of LOTUS Edge Valve System in IntermediatE Surgical Risk Subjects
Trial website
https://clinicaltrials.gov/show/NCT03618095
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Christopher U. Meduri, MD, MPH
Address 0 0
Piedmont Heart Institute
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Laoti Bussone, MPH
Address 0 0
Country 0 0
Phone 0 0
508-683-4337
Fax 0 0
Email 0 0
laoti.bussone@bsci.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT03618095